Ziagen

Ziagen. It is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of antiretroviral therapy for the treatment of HIV/AIDS. The medication is typically used in combination with other agents such as lamivudine and dolutegravir in fixed-dose combinations like Triumeq. Developed by the pharmaceutical company GlaxoSmithKline, it was approved for medical use in the United States in 1998 and has since become a cornerstone in global treatment guidelines issued by organizations like the World Health Organization.

Medical uses

Ziagen is indicated for the treatment of HIV-1 infection in both adults and children, always in combination with other antiretroviral agents to prevent the development of drug resistance. It is a key component of several preferred first-line regimens recommended by the U.S. Department of Health and Human Services and is also used in certain pre-exposure prophylaxis (PrEP) strategies. The drug is formulated both as a single agent and in fixed-dose combinations with medications like lamivudine and zidovudine (as Kivexa or Epzicom) or with lamivudine and dolutegravir. Prior to initiation, screening for the HLA-B*5701 allele is mandatory to significantly reduce the risk of a serious hypersensitivity reaction.

Adverse effects

The most serious adverse effect is a potentially fatal hypersensitivity reaction, which is strongly associated with the presence of the HLA-B*5701 allele; symptoms can include fever, rash, nausea, and respiratory signs. Other common side effects may include headache, insomnia, and fatigue. There is an observed association with an increased risk of myocardial infarction in some observational studies, though a definitive causal relationship remains debated among agencies like the Food and Drug Administration. Lactic acidosis and severe hepatomegaly with steatosis, while rare, are class effects of NRTIs and have been reported.

Pharmacology

Ziagen is a guanosine analogue that undergoes intracellular phosphorylation by cellular kinases to its active form, carbovir triphosphate. This active metabolite inhibits the activity of HIV-1 reverse transcriptase by competing with natural substrates like deoxyguanosine triphosphate and by incorporating into viral DNA, which results in chain termination. The drug is well-absorbed orally and is metabolized primarily by alcohol dehydrogenase and UDP-glucuronosyltransferase; its metabolism is not significantly affected by the cytochrome P450 system. Its activity spectrum is specific for retroviruses like HIV-1 and HIV-2.

History

The compound was discovered and developed by researchers at GlaxoSmithKline (formerly part of Burroughs Wellcome). It received approval from the Food and Drug Administration in December 1998, marking a significant addition to the NRTI class during a period of rapid advancement in antiretroviral therapy. A major milestone in its safety profile was the 2008 recommendation for mandatory HLA-B*5701 screening, following research led by institutions like the Western Australian Institute for Medical Research. Its inclusion in the World Health Organization's Model List of Essential Medicines underscores its global importance.

Society and culture

The drug is available under the brand name Ziagen and is also a critical component in widely used generic formulations distributed globally through programs like the U.S. President's Emergency Plan for AIDS Relief. Its development and associated pharmacogenetics screening represent a landmark example of personalized medicine in the field of infectious diseases. High-profile legal cases and activism, including efforts by groups like the AIDS Coalition to Unleash Power, have historically focused on drug access and pricing for antiretrovirals like abacavir. The medication has been studied in major clinical trials such as the Strategic Timing of Antiretroviral Treatment study and the D:A:D Study.

Category:Antiviral drugs Category:HIV/AIDS medications Category:World Health Organization essential medicines